Evidence map›Paper›PMID 42068671›Full record

ArticleTranslational oncology2026

Overexpression of NMNAT3 suppresses melanoma progression by reprogramming NAD⁺ metabolism.

Yan Wu, Jing Yu

Abstract read
In one paragraph

Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yan WuDepartment of Ophthalmology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China; Department of Ophthalmology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China.
Jing YuDepartment of Ophthalmology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China; Department of Ophthalmology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China; Department of Ophthalmology, The Third People's Hospital of Bengbu, Bengbu, China. Electronic address: 1300221@tongji.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMelanoma represents a highly aggressive and metastatic form of malignant skin cancer. that remains challenging to treat clinically. Tumor cells often reprogram nicotinamide adenine dinucleotide (NAD⁺) metabolism to meet the demands of rapid proliferation and metastasis, however, its function and mechanism in melanoma remain unclear. MATERIALS AND

methodsKey NAD⁺ metabolism-related genes associated with melanoma were screened using bioinformatic analysis of public databases (GEO and TCGA). Weighted Gene Co-expression Network Analysis (WGCNA) and machine learning approaches, further pinpointed NMNAT3 as a critical target for subsequent research. Confirmation of NMNAT3 expression on A375 melanoma cell line by qRT-PCR. Functional assays, including CCK-8 for proliferation, scratch wound for migration, and transwell for invasion, were employed to determine the roles of NMNAT3 in melanoma cells. Furthermore, an immune cell infiltration analysis was conducted to examine the association of NMNAT3 expression with the tumor immune microenvironment.

resultsBioinformatic analyses indicated a downregulation of NMNAT3 in melanoma tissues and cell lines, demonstrating significant diagnostic potential. Moreover, Immunoanalysis shows important links between NMNAT3 expression and invasive levels of various immunologic types within the melanoma tumour microenvironment. Subsequent in vitro functional studies further showed that that NMNAT3 overexpression can significantly inhibit the malignant phenotype of melanoma cells.

conclusionsThis study is the first to reveal the inhibitory role of NMNAT3 in melanoma growth. This study ensures an understanding of the theoretical principles of melanoma metabolic regulation and NMNAT3 treatment strategies.

Indexed as

bioinformaticsmalignant phenotypeMelanomaNAD(+) metabolismNMNAT3

Identifiers

PMID42068671
PMCPMC13147422

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.